glp 1 approved for nash glp-1 fatty liver Multiple target tissue effects of analogues on non-alcoholic disease (NAFLD) and non-alcoholic steatohepatitis (NASH) 🔬 Big news anyone – NASH drug treatment development: challenges

L-Carnitine Dosage Most studies have utilized a dose of 23 g of L-carnitine by mouth daily for adults

Safety still depends on design quality

Tirzepatide (Mounjaro, Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, not a pure GLP-1 agent

In the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015), participants receiving Saxenda alongside lifestyle modification achieved mean weight loss of approximately 8% of initial body weight, compared with 2.6% in the placebo group

~ AlphaMD Testosterone replacement therapy can affect more than lab results

Inflammation of the pancreas (pancreatitis)